---
document_datetime: 2023-09-21 18:17:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_en.pdf
document_name: adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6808183
conversion_datetime: 2025-12-28 19:40:14.657193
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form                                | Route of administration   | Immediate Packaging                                               | Content (concentration)               | Pack size                                     |
|------------------|-------------------|------------|----------------------------------------------------|---------------------------|-------------------------------------------------------------------|---------------------------------------|-----------------------------------------------|
| EU/1/09/578/001  | Adjupanrix        | 3.75 Âµg HA | Suspension and emulsion for emulsion for injection | Intramuscular use         | suspension (H5N1): vial (glass) emulsion (adjuvant): vial (glass) | 2.5 ml (suspension) 2.5 ml (emulsion) | 50 vials (suspension) 2 x 25 vials (emulsion) |